AT1 0.00% 2.6¢ atomo diagnostics limited

AT1 FY21 - General Discussion + FA, page-318

  1. 1,209 Posts.
    lightbulb Created with Sketch. 646
    @mdesai
    Sorry, think your Q got a bit lost amongst the ongoing discussion yesterday..

    Others might wish to post different opinions. My view (which I have posted+discussed with other SHs a few times) is that AT1 is still in a holding pattern...b/c its showing great potential, seems to be making all the right moves, building the right partnerships + foundations for long term growth (un-expectedly powered by Covid19 focus & hopefully lots of revenue but ultimately this will be one phase of many over next 20-30yrs).

    AT1's focus is not just to make extra rev from Covid19 sales, but to use that exposure to grow the diagnostic market awareness of their brand (in many other geos), showcase their technical capability to produce a unique device, continuing evolve their integrated device IP, showing their acumen in selecting the right partnerships to grow together etc

    At1 so far though has produced $5m rev in FY20..first time in its 10yr history (pre-IPO) and also turned cashflow positive in Q1'21. But the market has been awaiting lot more increased revenue trend (considering its MktCap of 125m+) to truly confirm Covid19, HIV, FebriDx etc growth potential does exist and this company is capitalising.

    its unclear why other diagnostics/Covid19 focused stocks keep increasing PE levels, even off a basic 'look-at-me' ann and no real sales or rev numbers VS in AT1's case, the SP keeps plateauing and staggering around the 30s. A very minor factor might be the AT1 number of shares (400-600m+ incl options). Per basic maths, it will take more share turnover to raise SP to 40c than another company that has 50% less shares on market t the same price.

    But number of shares shouldn't stop the SP from moving up significantly over next 1-2-3-4yrs, if the market sentiment changes based on rev numbers, more partnerships, pending US/India market approvals + proven test sales, higher HIV test sale numbers, stronger FebriDx expansion sales etc. AT1 has a lot of proven items in its pipeline...not just Covid19 focus..

    As to whether SP will downtrend to high 20s again, I'll leave it to any TA chartists to show trends/predictions. FA wise, nothing indicates to me this is going anywhere but north from here (we just don't know how long it will take).
    Last edited by FinFree101: 12/11/20
 
watchlist Created with Sketch. Add AT1 (ASX) to my watchlist
(20min delay)
Last
2.6¢
Change
0.000(0.00%)
Mkt cap ! $17.25M
Open High Low Value Volume
2.7¢ 2.7¢ 2.6¢ $71 2.691K

Buyers (Bids)

No. Vol. Price($)
1 40695 2.6¢
 

Sellers (Offers)

Price($) Vol. No.
2.7¢ 29109 2
View Market Depth
Last trade - 11.41am 17/07/2024 (20 minute delay) ?
AT1 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.